Gene polymorphisms in cyclophosphamide metabolism pathway,treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer.
about
Pharmacogenomics of breast cancer therapy: an updateCytochrome P450 Oxidoreductase Influences CYP2B6 Activity in Cyclophosphamide BioactivationCYP2B6rs2279343 Is Associated with Improved Survival of Pediatric Rhabdomyosarcoma Treated with CyclophosphamideCommon variants in genes coding for chemotherapy metabolizing enzymes, transporters, and targets: a case-control study of contralateral breast cancer risk in the WECARE Study.Effect of GSTP1 and ABCC4 gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-5-fluorouracil-based chemotherapy in Bangladeshi breast cancer patients.Through translational prospective study, the GSTP1 Ile105Val polymorphism emerges as prognostic marker in de novo large B-cell lymphoma patients.The GSTP1 105Val allele increases breast cancer risk and aggressiveness but enhances response to cyclophosphamide chemotherapy in North ChinaChemotherapy-induced neutropenia during adjuvant treatment for cervical cancer patients: development and validation of a prediction model.Leveraging epidemiology and clinical studies of cancer outcomes: recommendations and opportunities for translational researchFunctional polymorphisms in xenobiotic metabolizing enzymes and their impact on the therapy of breast cancer.Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevancePharmacogenetics of chemotherapy efficacy in breast cancer.Predictive biomarkers in breast cancer: their value in neoadjuvant chemotherapy.Effects of CYP2B6 genetic polymorphisms in patients receiving cyclophosphamide combination chemotherapy for breast cancer.Pharmacogenetics and breast cancer management: current status and perspectives.GSTP1, GSTM1, and GSTT1 polymorphisms as predictors of response to chemotherapy in patients with breast cancer: a meta-analysis.GSTP1 polymorphism predicts treatment outcome and toxicities for breast cancer.The Pharmacogenomic Association of Fcγ Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.Cytochrome P450 2J2, a new key enzyme in cyclophosphamide bioactivation and a potential biomarker for hematological malignancies.Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapy.Pharmacogenetic influence of GST polymorphisms on anthracycline-based chemotherapy responses and toxicity in breast cancer patients: a multi-analytical approach.Role of pharmacogenetics on adjuvant chemotherapy-induced neutropenia in Chinese breast cancer patients.Relationship of drug metabolizing enzyme genotype to plasma levels as well as myelotoxicity of cyclophosphamide in breast cancer patients.Pharmacogenetic association between GSTP1 genetic polymorphism and febrile neutropenia in Japanese patients with early breast cancer.Pathway-Based Analysis of Genome-Wide Association Data Identified SNPs in HMMR as Biomarker for Chemotherapy- Induced Neutropenia in Breast Cancer Patients.
P2860
Q27006783-C9AFFC0C-0715-451A-B942-7A78B6F5AF1EQ28550763-14811C08-6D45-4CA3-8118-F98AE0AEE20DQ28552450-F705E1DC-EAB1-4EF3-B09E-DFF4F696E5C1Q30418239-F14F3D2B-FFBE-41DE-AC26-00A60F3E0A65Q33420396-CBDC5E2C-1A5C-49E6-92A4-8E2899AE8FE0Q33701863-FC1B600F-9152-4F17-9E82-50248DF286C7Q34797388-6D36384A-0260-47FD-A73C-7FC4BF4F5119Q36046284-CA436E31-E28F-48F4-87AD-9793F1ED26DDQ36535678-ACB7EEF5-75CE-4E45-BC87-735B530F1D12Q36550926-7985C680-5382-47E1-9E47-C91D84037CA4Q36657589-84FD7A2B-4B0D-4E05-9069-03513006ADE0Q38003703-F66A3CEB-A4BF-415A-9404-7FB03868F960Q38047337-16E4B41B-8ECC-4E84-A0B1-1555582C4192Q38271855-C6FA1580-B7D9-4C05-AC20-F9478BCA885FQ38358816-3C374447-1E79-4AC4-91D2-D47CE7C99269Q38376375-E6C5FD0D-71DF-4959-83BB-2FD4B1C2E054Q42700718-2546455D-B79D-40C7-BA2C-2436E2CB4CABQ46250643-B59D1CBF-75AE-4C51-A3FA-372AB9352F91Q48234194-F54FBE56-5EFB-47DD-A38F-4A02617435B4Q49678698-24651CA3-669E-4655-B534-4A74C0180F55Q50868086-76FC6640-0D2F-4CE4-8918-E1E537FEEA92Q51297212-7EEDA87C-DB35-4998-A80F-1E8D22027EE4Q51399624-192DA990-0570-4521-8D0E-FDBF9C3B2FAFQ51711572-62CBFD1A-BC66-4831-A2A1-65B60233859FQ52723445-9C15700C-3F78-4F84-98FA-A39F6D3ABFE0
P2860
Gene polymorphisms in cyclophosphamide metabolism pathway,treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Gene polymorphisms in cyclopho ...... nical trial for breast cancer.
@ast
Gene polymorphisms in cyclopho ...... nical trial for breast cancer.
@en
Gene polymorphisms in cyclopho ...... nical trial for breast cancer.
@nl
type
label
Gene polymorphisms in cyclopho ...... nical trial for breast cancer.
@ast
Gene polymorphisms in cyclopho ...... nical trial for breast cancer.
@en
Gene polymorphisms in cyclopho ...... nical trial for breast cancer.
@nl
prefLabel
Gene polymorphisms in cyclopho ...... nical trial for breast cancer.
@ast
Gene polymorphisms in cyclopho ...... nical trial for breast cancer.
@en
Gene polymorphisms in cyclopho ...... nical trial for breast cancer.
@nl
P2093
P2860
P1476
Gene polymorphisms in cyclopho ...... nical trial for breast cancer.
@en
P2093
Alan P Lyss
C Kent Osborne
Daniel F Hayes
Gabriel N Hortobagyi
I-Tien Yeh
James M Rae
Ji-Yeob Choi
Kathy S Albain
Laura F Hutchins
P2860
P304
P356
10.1158/1078-0432.CCR-10-0281
P407
P577
2010-12-01T00:00:00Z